LPT 111111- A Single-Arm, Multicenter Phase II Study to Evaluate The Combination of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel or ABRAXANE) and Lapatinib (TYKERB) in Women With No More Than One Prior Treatment for ErbB2 Overexpressing Metastatic Breast Cancer.

Trial Profile

LPT 111111- A Single-Arm, Multicenter Phase II Study to Evaluate The Combination of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel or ABRAXANE) and Lapatinib (TYKERB) in Women With No More Than One Prior Treatment for ErbB2 Overexpressing Metastatic Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Lapatinib (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.
    • 01 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Mar 2017.
    • 01 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016 as reported byClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top